MedTrace Logo

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT01838499 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2016-09-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to gain initial evidence for the safety, tolerability and efficacy of MEDI8968 for the treatment of subjects with moderate to severe hidradenitis suppurativa

Conditions

Interventions

BIOLOGICAL

MEDI8968

SC injection at baseline, Week 4 and Week 8

BIOLOGICAL

Saline

SC injection at baseline, Week 4 and Week 8

Sponsors & Collaborators

  • ICON plc

    collaborator INDUSTRY

  • Covance

    collaborator INDUSTRY

  • PHT Corporation

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Robert AK Lee, MD · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01838499 on ClinicalTrials.gov